BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

TheraBiogen, Inc. (TRAB.OB) Signs Consulting Agreement With Mr. Dean Blechman, Former Head of Sales at Twinlab Corporation (TWLB), as Its New Corporate Advisor


5/30/2012 9:14:59 AM

NEW YORK, NY--(Marketwire - May 30, 2012) -

TheraBiogen, Inc. (OTCBB: TRAB), a manufacturer and distributor of homeopathic nasal sprays for aiding in the relief of allergies, cold and flu symptoms and migraine headaches, announced today that Dean Blechman, founding family member and former Executive Vice President of Sales at TWINLAB Corporation, agreed to become a consultant to the Company and assist the Company primarily in Sales & Marketing. As the former Executive Vice President of Sales at TWINLAB, Mr. Blechman was instrumental in growing TWINLAB's annual revenues from $5 million to over $330 million.

Dean Blechman stated: "I am very excited to be working with TheraBiogen, Inc. to help achieve its anticipated business goals and objectives. I believe the company has great potential and is well-positioned to achieve growth with its line of products. We have agreed that my immediate role will be to ensure that the significant systems and procedures are in place for the organization to run effectively and efficiently."

Additionally, Mr. Blechman may also advise the Company regarding TheraBiogen Inc.'s overall operations with its CEO, Kelly T. Hickel and two new members of its Board of Directors, Mr. Thomas Kelley and Mr. Pat Petruzzo.

Kelly Hickel, CEO of TheraBiogen, stated, "I will voluntarily offer my resignation to the Board of Directors within three months. This decision is best for the Company and the shareholders. I am very enthusiastic working with Dean Blechman during this time."

TheraBiogen's "Thera Max® Cold and Flu" product is an all-natural, non-zinc, non-addictive, over-the-counter cold and flu relief agent. Over 50 million Americans contract the flu each year and consumer demand for a homeopathic, non-zinc remedy is a 2.5 billion dollar market according to research studies.

Thera Max® is available for purchase in over twelve thousand locations including Rite-Aid, Food Lion, Hannaford Supermarkets, Discount Drug Marts and Big Y Supermarkets as well as two of the three largest drug retailers.

About TheraBiogen, Inc.
TheraBiogen, Inc. is a manufacturer and distributor of homeopathic nasal sprays for aiding in the relief of allergies, cold and flu symptoms and migraine headaches. The products are made from natural, homeopathic ingredients and contain no zinc, which has been identified as potentially causing nasal problems in other similar products on the market.

Information on Thera Max® can be obtained at http://gettheramaxrelief.com/, http://www.facebook.com/#!/TheraMaxNasalSpray and/or Twitter at http://twitter.com/theramaxrelief.

For information about this release contact Mr. Kelly Hickel at 866-284-9561, kthickel@therabiogen.com and/or Mr. Rich Kaiser, Investor relations, YES INTERNATIONAL, 757-306-6090, yes@yesinternational.com

Safe Harbor Statement
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21 E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that these forward-looking statements involve uncertainties and risk. These risks are set forth in the Company's most recently filed form 10-K and Form 10-Q reports. TheraBiogen, Inc. assumes no obligation to update the statements contained in this release except as required by applicable securities laws disclosure rules.


Contact:
Kelly T. Hickel
CEO
866-284-9561

Digg this    Bookmark with del.icio.us    Add to Newsvine

Technorati:


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->